EASL Video Podcasts

EASL DeepDive: Key Updates in the EASL Clinical Practice Guidelines on extrahepatic Cholangiocarcinoma (eCCA)

In this EASL DeepDive webinar, the expert panel presents and explains the key studies behind the latest recommendations included in the EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma.
Learning Objectives
To identify patients at risk for eCCA, and review the current tools and strategies for its surveillance, diagnosis, staging, and classification
To define the optimal candidates for resection and liver transplantation, and discuss challenges in the surgical management of eCCA
To discuss the role of systemic therapy in the management of eCCA across all disease stages (including neoadjuvant, adjuvant, and palliative settings)
Faculty
Luca Maroni - Moderator
Julie Heimbach - Speaker
Anna Saborowski - Speaker
Lars Aabakken - Speaker

EASL DeepDive: Key Changes in the New EASL HBV Guidelines

In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of hepatitis B virus infection, published in the "Journal of Hepatology" in 2025.
Learning objectives
Understand the updated EASL recommendations for initiating and discontinuing antiviral therapy in chronic hepatitis B, including key differences with other HBV guidelines. Participants will be able to identify treatment indications and make informed decisions about when and how to stop antiviral therapy.
Learn how to monitor patients with hepatitis B across different clinical scenarios, including those not on treatment, those receiving antiviral therapy, surveillance for hepatocellular carcinoma, risk of reactivation, and response to vaccination, in alignment with the new EASL guidelines.
Explore future directions in the management of chronic hepatitis B as outlined in the EASL guidelines, including advances in nomenclature and antiviral therapies under development.
Faculty
Markus Cornberg - Moderator
Maud Lemoine - Speaker
Sabela Lens - Speaker
Jerzy Jaroszewicz - Speaker

EASL DeepDive: EASL Clinical Practice Guidelines on the management of autoimmune hepatitis

In this EASL DeepDive, experts will discuss the latest advances in the EASL Clinical Practice Guidelines on the management of autoimmune hepatitis, published in the "Journal of Hepatology" in 2025.
Learning objectives
Select induction and maintenance treatment strategies aimed at achieving complete biochemical response
Recognise and manage disease flares, treatment intolerance, and suboptimal response in autoimmune hepatitis
Understand tailored approaches to autoimmune hepatitis management in specific patient groups
Faculty
Mária Papp - Moderator
Michael Heneghan - Speaker
George Dalekos - Speaker
Maria Carlota Londoño - Speaker

EASL DeepDive: The Pursuit of a Cure: HCC Management Strategies

Hepatocellular carcinoma (HCC) is responsible for 75% of all primary liver cancers and is the third most prevalent cause of cancer death worldwide, with 900,000 new cases diagnosed each year. Many patients are diagnosed at an advanced stage, making curative treatment difficult.
In this DeepDive Webinar, you’ll be guided through the latest advances in hepatocellular carcinoma management, from the rising impact of immunotherapy combinations to evolving approaches in intermediate-stage disease. 
This EASL DeepDive webinar is supported by Bayer AG. Bayer AG has had no input into the content of this EASL DeepDive.
Learning Objectives
What are strategies to optimise surveillance and early diagnosis of hepatocellular carcinoma
What are the optimal candidates for surgery (including liver transplantation) and locoregional therapies (alone or combined with immunotherapy)
Optimal selection of systemic front-line regimens and treatment sequencing after first-line immunotherapy
Faculty
Manon Allaire - Moderator
Fabio Piscaglia - Speaker
Antonio D'Alessio - Speaker
Anna Saborowski - Speaker

EASL Studio Podcast: Collaborating across disciplines to find the best solution for people living with PBC

This EASL Studio episode brings key insights from the 2025 EASL–AASLD Consensus Conference on Primary Biliary Cholangitis (PBC).
Experts explore the use of surrogate endpoints, the challenges in current trial design and regulation, the value of real-world evidence, and how quality-of-life assessment can support future pathways.
 
Moderator: David Jones
Speakers: Marco Carbone, Bettina Hansen, and Ana Lleo
 
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

EASL Studio Podcast: What Can Be Done to Safeguard Young Adults from SLD?

How can we protect young adults from steatotic liver disease (SLD)? This episode explores the burden of MASLD, MetALD, and ALD in Europe, the synergistic effects of alcohol and metabolic risk factors, and why the younger population is especially vulnerable. Experts also examine the disparities in risk factors and the role of clinics and policymakers in prevention.
Moderator: Shira Zelber Sagi
Speakers: Carina Ferreira-Borges (WHO representative) and Zobair Younossi
This EASL Studio is supported by Opella. EASL has received no input from Opella with regards to the content of this programme.
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

EASL Studio Podcast: Decoding AASLD The Liver Meeting: Trends Shaping Hepatology

What were the key takeaways from this year’s AASLD The Liver Meeting? In this episode, experts unpack the most impactful studies, clinical insights, and emerging trends shaping the future of hepatology. From liver cancer breakthroughs to MASLD, ALD, and beyond.
Moderator: Debbie Shawcross
Speakers: Saul Karpen, Allison Kwong, Mazen Noureddin
 
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

EASL Studio Podcast: Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance

For World Antimicrobial Awareness Week 2025 (“Act Now: Protect Our Present, Secure Our Future”), this EASL Studio explores the balance between rifaximin’s benefits in hepatic encephalopathy and the global challenge of antimicrobial resistance.
Moderator: Debbie Shawcross
Speakers: Rajiv Jalan, Vishal Patel, Jonel Trebicka
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
 
This EASL Studio is supported by Alfasigma and Norgine. EASL has received no input from Alfasigma or Norgine with regards to the content of this programme.

EASL Studio Podcast: Behind the Decision: How Can You Maximize Your Chances of Publication in JHEP Reports?

Ever wondered what happens to your manuscript after submission? In this episode, the JHEP Reports editorial team takes you behind the scenes: from first triage to reviewer selection, smart moves vs. red flags, and how final decisions are made. The discussion also explores the potential, limitations, and ethical pitfalls.
Moderator: Mattias Mandorfer
Speakers: Tobias Böttler, Virginia Hernández-Gea, and Josep Llovet
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.

EASL Studio Podcast: Are we finally entering an era of effective treatment for PSC?

After years of limited progress, recent trials hint at a changing landscape for primary sclerosing cholangitis (PSC). In this episode, experts review emerging data and explore whether we’re approaching a new era of effective treatment. How should clinicians assess these therapies, and could they shift the current management of PSC?
Moderator: Debbie Shawcross
Speakers:  Cynthia Levy, Stephen Rossi, Michael Trauner
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.